CTRI/2011/09/002024CompletedPhase 4
A Randomized , Open label, Comparative, study to evaluate the efficacy, safety and tolerability of Voglibose 0.3 mg + Fixed dose combination of Glimepiride 1 mg + Metformin (SR ) 500mg Vs fixed dose combination of Glimepiride 1 mg + Metformin (SR) 500 mg + Pioglitazone 15 mg in treatment of patients with Type II diabetes
Abbott Healthcare Pvt td0 sites44 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 44
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. >18 years of age, upper limit at the discretion of Investigator.
- •2.Patients diagnosed of type 2 diabetes as defined by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Appendix B) at least 6 months prior to screening
- •3.Patients with type 2 diabetes mellitus who had previously received at least 3 months of continuous treatment with oral monotherapy of Metformin 1000 mg and is inadequately controlled [HbA1c > 8% and HbA1c < 11 %] during screening visit
- •4.Patient with BMI between 20 ? 35 Kg/m2
- •5.Patients whose baseline fasting plasma venous glucose (FPG) concentration ranging from >126mg/dl but < 200mg/dl
- •6.Patients whose venous plasma glucose concentration is > 200 mg/dl at 2hr postprandial (after a meal) but < 300mg/dl
- •7.Patients with stable dietary and exercise pattern since three month and willing to follow the same for entire trial duration.
- •8.Ability to understand and the willingness to sign and date a written informed consent document at the screening visit before any protocol-specific procedures are performed.
Exclusion Criteria
- •1.Type-1 diabetes mellitus
- •2.Patients already on Insulin therapy.
- •3.H/O earlier use of dual or triple OAD¡¯s therapy.
- •4.Stroke, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or angina pectoris, within the last 12 months
- •5.Cardiac status New York Heart Association (NYHA) III-IV
- •6.Uncontrolled Blood pressure [ 140 Systolic and 90 Diastolic]
- •7.Impaired renal function as shown by, but not limited to, serum creatinine ¡Ý 1.5 mg/dL for males, or ¡Ý 1.4 mg/dL for females
- •8.Clinically significant peripheral edema
- •9.Acute infection
- •10.Acute or chronic history of metabolic acidosis, including diabetic ketoacidosis
- •11.Clinical evidence of active liver disease, or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2.5 times the upper limit of the normal range
- •12.Patients on steroids
- •13.Patient with anticipated need of surgery within study period.
- •14.Patient known to be suffering from any bleeding disorder.
- •15.Pregnancy or lactating women
- •16.Known hypersensitivity to any of the study drugs.
- •17.Any malignancy within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or adequately treated cervical carcinoma in situ
- •18.Current addiction or current alcohol abuse, or history of substance or alcohol abuse within the last 2 years
- •19.Diagnosis of dementia
- •20.Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- •21.Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
- •22.Any disease or condition that in the opinion of the investigator may interfere with the completion of the study
Investigators
Similar Trials
Not yet recruiting
Phase 2
A comparative Clinical study on the effect of Arjuna-RasonÄ?di yoga & Navaka guggulu On MedodushtiCTRI/2021/12/038393ational Institute Of Ayurveda deemed to be universityjaipur
Completed
Phase 3
A comparative study on efficacy , safety and reduction of diabetic complications, with regimens of metformin, glimeperide, &vildagliptin vs metformin, Glimeperide, & dapagliflozin in type â?? 2 diabetic patients.CTRI/2017/04/008424Siddhartha Medical College435
Completed
Phase 3
A comparative clinical study to evaluate efficacy and safety of fixed dose combination of Ceftriaxone + Sulbactam (CSE 1034) vs Ceftriaxone in patients suffering from various bacterial infectionsCTRI/2010/091/000174Venus Remedies Limited654
Completed
Phase 2
Comparative study to evaluate the Effectiveness of GanjhuVirTM a herbal antiviral in Cases of Dengue Fever with ThrombocytopeniaCTRI/2019/01/017096Radhika Ayurveda Research and Development
Completed
Phase 3
A clinical trial which is for various bacterial infectionsCTRI/2010/091/001046Venus Remedies Limited200